Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab (PROTECT)
Diabetes Mellitus - Type 1
What is the purpose of this trial?
The purpose of this study is to determine whether teplizumab slows the loss of β cells and preserves β cell function in children and adolescent 8-17 years old who have been diagnosed with T1D in the previous 6 weeks..
Subjects will receive two courses of either teplizumab or placebo treatment 6 months apart.
- Ages8 years - 17 years
- Trial withProvention Bio, Inc.
- Start Date09/10/2019
- End Date05/31/2022
- Last Updated07/15/2021
- Study HIC#2000025596